Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.

Author: AvernaMaurizio, ColhounHelen M, DonahueStephen, DuYunling, FarnierMichel, HanotinCorinne, JonesPeter, SeveranceRandall, Steinhagen-ThiessenElisabeth

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adding alirocumab to rosuvastatin significantly reduced low-density lipoprotein cholesterol (LDL-C) levels compared to adding ezetimibe or doubling the rosuvastatin dose. About 80% of patients maintained the 75mg Q2W alirocumab dose, and 84.9% (baseline rosuvastatin 10 mg) and 66.7% (baseline rosuvastatin 20 mg) achieved their LDL-C targets.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053). METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection v...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.atherosclerosis.2015.11.010

データ提供：米国国立医学図書館（NLM）

Lowering Cholesterol Levels: A Comparison of Alirocumab, Ezetimibe, and Rosuvastatin

This research examines the lipid-lowering efficacy of alirocumab, a PCSK9 inhibitor, in comparison to ezetimibe and doubling the dose of rosuvastatin in patients with high cardiovascular risk. The authors conducted a randomized controlled trial, the ODYSSEY OPTIONS II study, to compare the effectiveness of these treatments in reducing LDL-C levels. Their findings demonstrate significantly greater LDL-C reductions with alirocumab compared to ezetimibe or doubling the rosuvastatin dose, particularly in patients receiving rosuvastatin 10 mg at baseline. The study highlights the potential of alirocumab as a powerful tool for achieving LDL-C targets in patients with high cardiovascular risk.

Alirocumab: A Powerful Tool for Lowering Cholesterol

This research provides compelling evidence for the efficacy of alirocumab in achieving significant LDL-C reductions in patients with high cardiovascular risk. The study highlights alirocumab's potential for improving cardiovascular health outcomes by effectively lowering LDL-C levels.

Managing Cholesterol Levels: Making Informed Choices

High cholesterol levels can increase the risk of cardiovascular disease. This research provides valuable insights into the efficacy of various treatment options for lowering cholesterol, allowing patients to make informed decisions about their healthcare.

Dr.Camel's Conclusion

This research, like a steady camel caravan crossing the desert, provides a clear path for lowering cholesterol levels. Alirocumab, with its impressive LDL-C reduction capabilities, emerges as a promising tool for improving cardiovascular health.

Date :
  1. Date Completed 2016-10-11
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

26638010

DOI: Digital Object Identifier

10.1016/j.atherosclerosis.2015.11.010

Related Literature

Article Analysis
・Effects of alirocumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.